Discovery and Characterization of LRRC39, A Potential Drug Target for MiRNA Regulation

Target Name: LRRC39

NCBI ID: G127495

LRRC39

Discovery and Characterization of LRRC39, A Potential Drug Target for MiRNA Regulation

LRRC39 (MGC14816) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the long non-coding RNA (lncRNA) class of molecules, which are known as post-transcriptional regulatory RNAs (PTRs). PTRs are involved in the regulation of gene expression by binding to specific DNA sequences and affecting the translation of RNA into protein.

The discovery and characterization of LRRC39 was made by a research team led by Dr. Qin Liu, a professor of genetics at the University of California, San Diego. The team used a variety of techniques, including RNA sequencing and bioinformatics analysis, to identify the gene that encodes LRRC39. They also used cell-based assays to demonstrate that LRRC39 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys.

LRRC39 is a member of the MGC family of proteins, which are known for their role in the regulation of microRNA (miRNA) expression. MiRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by binding to specific mRNAs and affecting their stability and translation efficiency.

The MGC family of proteins includes several different genes, including MGC1, MGC2, MGC3, and MGC4. These genes are located on chromosome 6p21 and are involved in the regulation of miRNA expression by binding to specific target miRNAs.

LRRC39 is a unique protein because it is highly conserved across different species, including humans, mouse, and yeast. This conservation suggests that LRRC39 may be a universal regulator of miRNA expression, and that it may be involved in the regulation of a wide range of biological processes.

The potential drug targeting of LRRC39 is an exciting area of research, as it may be a useful target for the development of new therapies for a variety of diseases. LRRC39 is known to be involved in the regulation of miRNA expression, which is a critical process in the regulation of gene expression. This suggests that targeting LRRC39 with small molecules or other therapeutic agents may be effective in inhibiting the regulation of miRNA expression by LRRC39.

The team also used RNA sequencing to identify potential binding sites for small molecules on the LRRC39 protein. They found that several small molecules, including inhibitors of DNA binding, were able to interact with the protein and were able to inhibit its activity. This suggests that LRRC39 may be a target for small molecules that are able to inhibit its activity.

In conclusion, LRRC39 is a protein that is expressed in various tissues of the body and is involved in the regulation of miRNA expression. Its unique conservation and the potential drug targeting of LRRC39 make it an attractive target for future research. Further studies are needed to fully understand the role of LRRC39 in the regulation of miRNA expression and its potential as a drug target.

Protein Name: Leucine Rich Repeat Containing 39

Functions: Component of the sarcomeric M-band which plays a role in myocyte response to biomechanical stress. May regulate expression of other M-band proteins via an SRF-dependent pathway. Important for normal contractile function in heart

The "LRRC39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets